Qiming Venture Partners

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.

IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

Complete Omics is a company focused on the development of multi-omics diagnostics for early disease detection, particularly in cancer. The firm specializes in creating personalized diagnosis and treatment platforms that leverage advanced technologies across various omics fields. With patented innovations, Complete Omics offers precision companion diagnostics that enhance the ability to conduct sensitive and specific health surveillance tests. By enabling researchers and pharmaceutical companies to utilize these sophisticated tools, Complete Omics aims to improve diagnosis and treatment outcomes in the field of oncology.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Boulder Care, established in 2017 and headquartered in Portland, Oregon, specializes in telemedicine-based programs for opioid addiction treatment. The company offers comprehensive services including medication-assisted treatment with buprenorphine, peer support, patient counseling, and psychosocial services to aid recovery. Boulder Care serves patients directly, as well as healthcare providers and organizations seeking to expand access to effective opioid addiction treatment.

Ceptur Therapeutics is focused on developing innovative genetic medicines for patients with unmet medical needs. The company utilizes its proprietary U1 Adaptor technology to achieve non-genotoxic, long-lasting silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and has potential applications in cancer treatment, allowing healthcare providers to offer new therapeutic options for various cancer types. Through its advancements, Ceptur aims to improve patient outcomes by providing effective solutions for difficult-to-treat conditions.

Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.

ShanZhen is a health service platform focused on addressing the physical health and pension needs of individuals born in the 1980s and 1990s. The company provides affordable regular health checkups, personalized health management plans, and insurance options. Additionally, it offers medical examination services and data finance products aimed at mitigating the challenges posed by an aging population and the rising prevalence of chronic diseases. Through its comprehensive services, ShanZhen seeks to enhance the quality of life for elderly patients, promoting healthier and happier living conditions.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression for organ transplant recipients. The company's leading product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all chronic immunosuppression therapy within twelve months post-transplant. In addition to its applications in organ transplantation, Talaris’s technology facilitates the safe use of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, reducing the associated toxicity and risks of traditional methods. Founded in 1988 and originally named Regenerex, Inc., Talaris Therapeutics rebranded in March 2019. The company is headquartered in Louisville, Kentucky, with an additional office in Wellesley, Massachusetts.

Health Game Advice: Resist bad games, refuse pirated games, pay attention to self-protection, beware of being deceived, moderate games to benefit the brain, indulge in game injuries, arrange time properly and enjoy a healthy life.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

ShanZhen is a health service platform focused on addressing the physical health and pension needs of individuals born in the 1980s and 1990s. The company provides affordable regular health checkups, personalized health management plans, and insurance options. Additionally, it offers medical examination services and data finance products aimed at mitigating the challenges posed by an aging population and the rising prevalence of chronic diseases. Through its comprehensive services, ShanZhen seeks to enhance the quality of life for elderly patients, promoting healthier and happier living conditions.

Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression for organ transplant recipients. The company's leading product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all chronic immunosuppression therapy within twelve months post-transplant. In addition to its applications in organ transplantation, Talaris’s technology facilitates the safe use of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, reducing the associated toxicity and risks of traditional methods. Founded in 1988 and originally named Regenerex, Inc., Talaris Therapeutics rebranded in March 2019. The company is headquartered in Louisville, Kentucky, with an additional office in Wellesley, Massachusetts.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

Cardialen, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in developing innovative therapies for heart arrhythmias, particularly atrial fibrillation. Founded in 2008, the company focuses on creating implantable devices that provide low-energy, pain-free cardioversion therapies to restore normal heart rhythm. These devices utilize a proprietary technology that delivers a sequential series of low-voltage pulses to effectively address atrial fibrillation and other related conditions, such as rapid ventricular tachycardia and ventricular fibrillation, while minimizing patient discomfort and protecting heart tissue from damage. By targeting significant unmet medical needs, Cardialen aims to improve the quality of life for individuals suffering from these heart conditions.

IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

Health Game Advice: Resist bad games, refuse pirated games, pay attention to self-protection, beware of being deceived, moderate games to benefit the brain, indulge in game injuries, arrange time properly and enjoy a healthy life.

QIAGEN Suzhou is an innovative start-up providing precision medicine solutions.

Twine Health, Inc. is a cloud-based software platform focused on chronic care management. Founded in 2012 and based in Cambridge, Massachusetts, Twine Health provides tools for shared decision-making, enabling patients and clinicians to collaboratively set health goals and evaluate management options. Its platform includes self-tracking tools that empower patients to take control of their conditions, dashboards for clinicians to monitor patient progress, and integrated messaging features to facilitate communication. Twine Health also offers a patient engagement portal, a peer support network, and an outcome analytics tool, all designed to foster collaboration among patients, healthcare providers, and support teams such as nurses and health coaches. The platform aims to enhance patient self-efficacy and improve health outcomes through continuous, personalized care.

ZappRx is a digital health company based in Boston, Massachusetts, founded in 2012. It specializes in providing a cloud-based platform that streamlines the process of ordering specialty medications for healthcare providers, specialty pharmacies, and biopharma companies. The platform facilitates secure digital interactions among providers, pharmacists, and payers, reducing reliance on traditional methods like faxes and phone calls. By automating prescription management and prior authorization processes, ZappRx enhances efficiency in collecting and maintaining necessary information for specialty prescribing. This includes details such as pharmacy information, payer requirements, and clinical history. The company's platform is utilized across various medical fields, including pulmonary, cardiology, and gastroenterology.

IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

LIH Investment & Management manages and invests in rehabilitation medical institutions. The Company serves customers in China. LIH Investment & Management has always been devoted to invest, manage and operate high-quality rehabilitation medical service organization, introduce internationalization concept, technology and mode into China, promote the professional medical rehabilitation service and management and continuous innovation.

Junhetang is a prominent operator of traditional Chinese medicine clinics, specializing in a range of therapies and healthcare services. The company has established a network of clinics that provide traditional Chinese medicines, including herbal medicine, acupuncture, massage, and dietary therapies. By integrating TCM culture with the expertise of renowned practitioners, Junhetang aims to offer personalized medical services that cater to individual health needs. Additionally, the company leverages convenient internet services to enhance its healthcare management and service delivery. Headquartered in Nanjing, Junhetang is actively expanding its presence across various cities in China, including Shanghai, Shenzhen, Chengdu, and Taiyuan, thereby broadening access to traditional Chinese medicine for a wider audience.

LIH Investment & Management manages and invests in rehabilitation medical institutions. The Company serves customers in China. LIH Investment & Management has always been devoted to invest, manage and operate high-quality rehabilitation medical service organization, introduce internationalization concept, technology and mode into China, promote the professional medical rehabilitation service and management and continuous innovation.

JHT TCM Clinics

Junhetang is a prominent operator of traditional Chinese medicine clinics, specializing in a range of therapies and healthcare services. The company has established a network of clinics that provide traditional Chinese medicines, including herbal medicine, acupuncture, massage, and dietary therapies. By integrating TCM culture with the expertise of renowned practitioners, Junhetang aims to offer personalized medical services that cater to individual health needs. Additionally, the company leverages convenient internet services to enhance its healthcare management and service delivery. Headquartered in Nanjing, Junhetang is actively expanding its presence across various cities in China, including Shanghai, Shenzhen, Chengdu, and Taiyuan, thereby broadening access to traditional Chinese medicine for a wider audience.

MedSci provides strategies, solutions and services to pharmaceutical, biotechnology and medical device organizations as well as the consumer healthcare industry. It offers clinical research, medical affairs, marketing and consulting services. It operates online professional physician platforms in China and provides physician platform solutions, precision omni-channel marketing solutions and real-world study solutions there.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

JHT TCM Clinics

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.